Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Mar 17 09:43AM ET
1.42
Dollar change
-0.01
Percentage change
-0.69
%
Index- P/E- EPS (ttm)-1.66 Insider Own7.66% Shs Outstand41.10M Perf Week2.53%
Market Cap58.37M Forward P/E- EPS next Y-0.12 Insider Trans0.00% Shs Float37.95M Perf Month2.17%
Income-67.25M PEG- EPS next Q-0.36 Inst Own51.47% Short Float1.26% Perf Quarter39.23%
Sales0.00M P/S- EPS this Y89.66% Inst Trans-0.60% Short Ratio0.39 Perf Half Y100.01%
Book/sh2.51 P/B0.57 EPS next Y33.33% ROA-45.13% Short Interest0.48M Perf Year16.40%
Cash/sh2.09 P/C0.68 EPS next 5Y- ROE-52.41% 52W Range0.63 - 1.44 Perf YTD24.57%
Dividend Est.- P/FCF- EPS past 5Y- ROI-65.21% 52W High-1.38% Beta1.16
Dividend TTM- Quick Ratio6.04 Sales past 5Y0.00% Gross Margin- 52W Low125.41% ATR (14)0.03
Dividend Ex-Date- Current Ratio6.04 EPS Y/Y TTM3.33% Oper. Margin- RSI (14)70.34 Volatility1.80% 1.44%
Employees215 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom4.00 Target Price0.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-18.29% Payout- Rel Volume0.04 Prev Close1.43
Sales Surprise- EPS Surprise-17.07% Sales Q/Q- EarningsNov 14 BMO Avg Volume1.23M Price1.42
SMA202.15% SMA5010.22% SMA20041.23% Trades Volume4,075 Change-0.69%
Date Action Analyst Rating Change Price Target Change
Apr-05-24Downgrade Piper Sandler Overweight → Neutral $8 → $2
Apr-26-21Initiated Piper Sandler Overweight $25
Apr-26-21Initiated Oppenheimer Outperform $23
Apr-26-21Initiated JP Morgan Underweight $11
Apr-26-21Initiated Chardan Capital Markets Buy $27
Apr-26-21Initiated BofA Securities Buy $20
Feb-28-25 07:00AM
Dec-25-24 09:35AM
Dec-24-24 09:30AM
Nov-19-24 07:00AM
Nov-14-24 07:00AM
09:40AM Loading…
Sep-23-24 09:40AM
Sep-19-24 07:00AM
Aug-14-24 07:00AM
May-22-24 07:00AM
May-17-24 05:00PM
May-08-24 01:53PM
07:00AM
Apr-04-24 11:53AM
06:45AM
06:30AM
07:00AM Loading…
Feb-05-24 07:00AM
Dec-18-23 07:00AM
Nov-13-23 04:30PM
Oct-24-23 12:30PM
Sep-22-23 04:30PM
09:40AM
Sep-13-23 12:05PM
Sep-06-23 09:40AM
Aug-10-23 11:50AM
Aug-04-23 07:00AM
Jun-12-23 08:00AM
May-21-23 10:03AM
May-10-23 07:15AM
07:00AM
Apr-25-23 06:00PM
07:00AM Loading…
07:00AM
Apr-22-23 09:45AM
Apr-17-23 08:00AM
Mar-07-23 07:00AM
Feb-02-23 09:40AM
Jan-17-23 09:40AM
Dec-20-22 08:30AM
Dec-06-22 06:00AM
Nov-30-22 06:05PM
Nov-22-22 08:00AM
Nov-13-22 07:48AM
Nov-08-22 07:00AM
Nov-01-22 12:00PM
Oct-06-22 08:30AM
Sep-07-22 01:15PM
Aug-31-22 12:53PM
Aug-26-22 01:34PM
Aug-25-22 11:53AM
Aug-24-22 01:33PM
Aug-23-22 01:53PM
Aug-19-22 12:32PM
Aug-16-22 10:09AM
Aug-09-22 07:00AM
Aug-01-22 06:00AM
Jul-21-22 08:00AM
Jun-30-22 08:00AM
Jun-21-22 08:30AM
Jun-06-22 08:40AM
May-10-22 07:00AM
May-09-22 07:00AM
May-04-22 08:00AM
May-03-22 08:00AM
Apr-14-22 11:27AM
Apr-12-22 07:30AM
07:30AM
Apr-05-22 08:00AM
Apr-04-22 08:00AM
Mar-08-22 08:00AM
Mar-01-22 09:00AM
07:02AM
04:00AM
Feb-07-22 07:30AM
Jan-13-22 07:30AM
Dec-28-21 04:09AM
Dec-21-21 08:00AM
Dec-20-21 08:00AM
Dec-09-21 07:00AM
Nov-12-21 07:00AM
Nov-10-21 08:15AM
Nov-09-21 08:00AM
Oct-22-21 07:30AM
Oct-12-21 08:00AM
Oct-01-21 08:00AM
Sep-29-21 06:15AM
Sep-02-21 08:30AM
Aug-25-21 08:00AM
Aug-10-21 07:00AM
Jul-26-21 03:00PM
Jul-01-21 08:00AM
04:40AM
Jun-04-21 09:00AM
May-11-21 07:00AM
May-06-21 08:00AM
May-05-21 08:30AM
May-03-21 08:00AM
Apr-10-21 08:30AM
Apr-06-21 04:01PM
Mar-31-21 02:01PM
Mar-30-21 07:00PM
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coutts Robert WilliamOfficerMar 03 '25Proposed Sale1.204,1685,006Mar 03 09:52 AM
Ali IrajDirectorMar 03 '25Proposed Sale1.229,37611,466Mar 03 09:43 AM
Coutts Robert WilliamOfficerFeb 13 '25Proposed Sale1.06334355Feb 18 06:37 AM
Ehmer BernhardDirectorFeb 06 '25Proposed Sale1.3838,75053,537Feb 11 12:48 PM
Moses EdwinDirectorFeb 06 '25Proposed Sale1.3825,00034,500Feb 07 01:32 PM
Giordano Michael FFormer DirectorFeb 04 '25Proposed Sale1.3925,00034,815Feb 06 12:55 PM
BOESS CARSTENDirectorFeb 04 '25Proposed Sale1.3625,00034,004Feb 06 12:50 PM
O'Neill JulieFormer DirectorFeb 04 '25Proposed Sale1.3725,00034,250Feb 06 12:39 PM
Ali IrajDirectorFeb 04 '25Proposed Sale1.2950,00064,453Feb 06 07:15 AM
Quezada Sergio AndresFormer OfficerFeb 04 '25Proposed Sale1.3767,43792,265Feb 05 02:06 PM
Coutts Robert WilliamOfficerFeb 05 '25Proposed Sale1.2375,02491,956Feb 05 12:46 PM